New Delhi, Jan. 20 -- US-based biopharmaceutical company, RAPT Therapeutics' stock surged more than 63% during the pre-market trading session on the US stock market's Nasdaq after GSK Plc announced its $2.2 billion equity value acquisition deal, according to the official filing.

RAPT Therapeutics' stock jumped more than 63% to $57.45 during the premarket trading session on the US stock market on Tuesday after the acquisition update, compared to $35.10 at the previous market close, according to MarketWatch data on Tuesday.

After Monday's trading session, RAPT stock closed 9.04% higher at $35.10, according to the market data.

Shares of RAPT Therapeutics have lost 79% in the last five years. However, the company's stock has given US marke...